Trasylol Use During Heart Surgery Linked to Kideny Failure & Death

Send to Friend | Bookmark | Live Chat

Recently, researchers have suggested that Trasylol use may have cost 22,000 lives. Dr. Dennis Mangano released a groundbreaking study as far back as 2006, where he estimated that Trasylol use during Coronary Artery Bypass Graft surgery may have contributed to the death of over 1,000 people per month.

The use of Trasylol during heart surgeries has been linked to an increased risk of death, kidney or renal failure, heart attacks, strokes and encephalopathy among heart surgery patients.

Schmidt & Clark has been actively pursuing Trasylol side effect cases since 2006. The Defective Drug Litigation Group at our law firm is an experienced team of trial lawyers that focus exclusively on the representation of plaintiffs in Trasylol lawsuits. We are handling individual litigation nationwide and currently accepting new Trasylol cases in all 50 states.

If you or a loved one have undergone heart surgery and subsequently developed kidney or renal failure and are now undergoing dialysis treatments or have passed away, you should contact us immediately by using the form below or dialing (866) 588-0600. You may be entitled to compensation by filing a Trasylol lawsuit and we can help.

Bayer Recalls Heart Surgery Medication Trasylol

On November 5, 2007, the U.S. Food and Drug Administration (FDA) announced that, at the agency's request, Bayer Pharmaceuticals Corp. agreed to a marketing suspension of Trasylol, a drug used to control bleeding during heart surgery, pending detailed review of preliminary results from a Canadian study that suggested an increased risk for death.

Since that time, CBS 60 minutes has recently released, “1,000 Lives Per Month”, a groundbreaking video that has brought the Trasylol tragedy to light.

In addition, on February 21, 2008, two studies were released by the New England Journal of Medicine, wherein both studies confirm that the use of Trasylol causes an increased risk of death and kideny damage when compared to other alternative medicines or no medicine at all.

Watch the full length video below.

What is Trasylol?

Trasylol (Generic: aprotinin) is an injectable prescription drug which inhibits certain enzymes that increase the risk of bleeding during surgery and aids the body's ability to prevent bleeding.

Normally, the drug is given to patients undergoing heart bypass surgery to control blood loss, but has also been used in other surgeries, such as hip replacement surgery.

Trasylol is manufactured by Bayer Pharmaceuticals Corporation and was approved by the Food and Drug Administration in December 1993 to reduce bleeding and the need for blood transfusion in patients undergoing heart surgery.

Learn More: Trasylol Recall

11/5/07: FDA Requests Marketing Suspension of Trasylol

12/15/06: FDA Trasylol Label Change and Warning

12/15/06: MedWatch Trasylol Adverse Event Report

Must Read: FDA Trasylol Resource Page

Do I have a Trasylol Lawsuit?

The Defective Drug Litigation Group at our law firm is an experienced team of trial lawyers that focus exclusively on the representation of plaintiffs in Trasylol lawsuits. We are handling individual litigation nationwide and currently accepting new Trasylol cases in all 50 states.

Again, If you or a loved one have undergone heart surgery and subsequently developed kidney or renal failure and are now undergoing dialysis treatments or have passed away, you should contact us immediately by using the form below or dialing (866) 588-0600. You may be entitled to compensation by filing a Trasylol lawsuit and we can help.

Attention Attorneys: We do not publish prior verdict/settlements. If you are an attorney and would like to refer us a case or for us to send you a profile of prior award judgments or average referral fees, please visit the attorney referral section of our website.

= Required Field

Trasylol Heart Surgery News (National)

Heart-surgery drug pulled from U.S. market - HealthCentral.com BOSTON (Reuters) - Bayer AG is removing remaining supplies of its heart-surgery drug Trasylol from the U.S. market after a long-awaited study found it raised the risk of death compared to two alternatives, U.S. regulators said on Wednesday. The ... Danger From Heart Surgery Drug Confirmed - BusinessWeek WEDNESDAY, May 14 (HealthDay News) -- A new Canadian study confirms that people given Trasylol, a drug used to reduce bleeding during heart surgery, increases their risk of death by 53 percent. Trasylol's German maker, Bayer AG, suspended marketing ... Bayer pulls Trasylol supplies after study - MSN MoneyCentral BOSTON (Reuters) - Bayer AG is removing remaining supplies of its heart-surgery drug Trasylol from the U.S. market after a long-awaited study found it raised the risk of death compared to two alternatives, U.S. regulators said on Wednesday. The ... Study likely spells end for anti-bleeding drug - The Ledger An anti-bleeding drug probably will stay off the market, experts say, after a rigorous study found patients getting the medication during heart surgery were much more likely to die than patients given other drugs. Bayer AG, the maker of the drug ... US FDA: Bayer to remove rest of Trasylol supplies - Reuters WASHINGTON, May 14 (Reuters) - Bayer AG (BAYG.DE: Quote , Profile , Research ) will start removing the remaining supplies of its heart-surgery drug Trasylol from the U.S. market, the Food and Drug Administration said on Wednesday. Access to the drug ... Study likely spells end for anti-bleeding drug Trasylol, temporarily ... - Minneapolis Star Tribune An anti-bleeding drug probably will stay off the market, experts say, after a rigorous study found patients getting the medication during heart surgery were much more likely to die than patients given other drugs. Study May Mean End for Anti-Bleeding Drug Trasylol - The Ledger An anti-bleeding drug probably will stay off the market, experts say, after a rigorous study found patients getting the medication during heart surgery were much more likely to die than patients given other drugs. Bayer AG, the maker of the drug ... Bayer pulls anti-bleeding drug after study - MSNBC Bayer AG is removing remaining supplies of its heart-surgery drug Trasylol from the U.S. market after a rigorous study found patients getting the medication during heart surgery were much more likely to die than patients given other drugs, U.S ... Bayer to remove Trasylol from the market, FDA - The Money Times Bayer HealthCare Pharmaceuticals Inc. is going to remove the remaining supplies of its heart-surgery drug, Trasylol from the market. This has been decided after a study on this drug revealed that it increased the risk of death, heart attack and ... Study links drug to higher death rate in heart surgery - Fort Lauderdale Sun-Sentinel An anti-bleeding drug probably will stay off the market, experts say, after a rigorous study found patients getting the medication during heart surgery were much more likely to die than patients given other drugs. Bayer AG, the maker of Trasylol ...